BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

Official Title
-----------------
Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: Riociguat (Adempas, BAY63-2521)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1 Exclusion Criteria: Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Riociguat (Adempas, BAY63-2521)<br>* BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Treatment-emergent Adverse Events (TEAE) | Analyses of drug-related TEAEs were based on the assessment of causal relationship to study medication. | From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years | 
| Number of Participants With Death | Analyses of deaths were based on the assessment of causal relationship to study medication. The safety follow-up visit was to be performed 30 days after the last dose of riociguat. | From baseline to end of safety follow-up visit, up to 10 years (1 month more than End of study visit) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With Treatment-emergent High Laboratory Abnormalities in Hematology and Coagulation | Frequency of participants only with a treatment-emergent shift in hematology and coagulation parameters from normal or low at baseline to a high value at a timepoint after the start of treatment. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 
| Percentage of Participants With Treatment-emergent Low Laboratory Abnormalities in Hematology and Coagulation | Frequency of participants only with a treatment-emergent shift in hematology and coagulation parameters from normal or high at baseline to a low value at a timepoint after the start of treatment. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 
| Change From Baseline of Hemoglobin in Hematology and Coagulation | Hemoglobin is standard Hematology and coagulation parameter. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 
| Percentage of Participants With Treatment-emergent High Laboratory Abnormalities in Clinical Chemistry | Frequency of participants per treatment group only with a treatment-emergent shift in clinical chemistry parameters from normal or low at baseline to a high value at a timepoint after the start of treatment. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 
| Percentage of Participants With Treatment-emergent Low Laboratory Abnormalities in Clinical Chemistry | Frequency of participants per treatment group only with a treatment-emergent shift in clinical chemistry parameters from normal or high at baseline to a low value at a timepoint after the start of treatment. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 
| Change From Baseline of Urate in Clinical Chemistry | Urate is standard clinical chemistry parameter. A termination visit was only to be performed in the case of premature termination of study medication or if the sponsor announced the official end of the study. | From baseline to Termination visit, up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic thromboembolic Hypertension, PH, soluble Guanylate Cyclase Stimulator, sGC